[Hematology 2010].
Dreyling
M
M
Medizinische Klinik III der Universität München - Grosshadern, München. Martin.Dreyling@med.uni-muenchen.de
Subklewe
M
M
Braess
J
J
Spiekermann
K
K
D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016503:Drug Delivery Systems; D006402:Hematologic Diseases / Q000175:diagnosis / Q000628:therapy*; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000628:therapy; D008224:Lymphoma, Follicular / Q000175:diagnosis / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000628:therapy; D009101:Multiple Myeloma / Q000175:diagnosis / Q000628:therapy; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000628:therapy; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis / Q000628:therapy
D000925:Anticoagulants; D000970:Antineoplastic Agents